McKesson Corporation (MCK) is a publicly traded company in the Healthcare — Medical - Distribution industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S.
Analysis Summary
McKesson Corporation reported revenue of $403.43B in the most recent fiscal year, growing at a 5-year CAGR of 11.1%.
Trailing-twelve-month margins: gross margin 3.6%, operating margin 1.6%, net margin 1.1%. Free cash flow grew at 6.8% CAGR over 5 years.
At the current price of $874.65, MCK trades at a P/E of 22.99 and an ROE of -194.39%. Market capitalisation stands at $102.4B, placing it among large-cap names.
Balance sheet quality for MCK: current ratio of 0.9, net debt of $4.64B. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $5.41B represents 114% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $874.65 |
| Market Cap | $102.4B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 22.99 |
| Price / Book | -24.15 |
| EV / EBITDA | 15.30 |
| Dividend Yield | 0.39% |
Profitability
| Return on Equity | -194.39% |
| Return on Invested Capital | 27.91% |
| Return on Assets | 5.20% |
| Gross Margin | 3.64% |
| Operating Margin | 1.62% |
| Net Margin | 1.12% |
Financial Health
| Debt / Equity | -2.76 |
| Current Ratio | 0.89 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 6.17 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MCK | McKesson Corporation | $102.4B | 22.99 | -194.4% | |
| SNY | Sanofi | $102.0B | 22.49 | 1.27 | 5.5% |
| BMY | Bristol-Myers Squibb Company | $128.8B | 13.70 | 5.69 | 46.8% |
| GSK | GSK plc | $96.4B | 15.65 | 4.27 | 35.0% |
| MDT | Medtronic plc | $117.9B | 22.29 | 2.32 | 10.6% |
| HCA | HCA Healthcare, Inc. | $92.4B | 14.28 | -112.9% | |
| CVS | CVS Health Corp. | $117.0B | 23.06 | 1.41 | 2.4% |
| COR | Cencora, Inc. | $62.0B | 22.89 | 19.59 | 106.4% |
Price Performance
| 1 month | +4.28% |
| 3 months | +16.52% |
| Year-to-date | +6.63% |
| 1 year | +25.25% |
| 3 years | +98.85% |
| 5 years | +333.23% |
52-Week Range
| 52-week High | $999.00 |
| 52-week Low | $687.68 |
| Avg Volume (90d) | 1.1M |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2026-09-01 | $0.9400 | 0.43% |
| 2026-06-01 | $0.8200 | 0.38% |
| 2026-03-02 | $0.8200 | 0.38% |
| 2025-12-01 | $0.8200 | 0.38% |
| 2025-09-02 | $0.8200 | 0.38% |
| 2025-06-02 | $0.7100 | 0.32% |
| 2025-03-03 | $0.7100 | 0.32% |
| 2024-12-02 | $0.7100 | 0.32% |
| 2024-08-30 | $0.7100 | 0.32% |
| 2024-06-03 | $0.6200 | 0.28% |
Related companies: BMY · CAH · COR · CVS · GSK · HCA · MDT
Explore sector: Healthcare · Medical - Distribution
More sections of MCK: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks